Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types.

Abstract excerpt

We evaluated the impact of class I and class II human leukocyte antigen (HLA) genotypes, heterozygosity, and diversity on the efficacy of pembrolizumab. Seventeen pembrolizumab clinical trials across eight tumor types and one basket trial in patients with advanced solid tumors were included (n > 3,500 analyzed). Germline DNA was genotyped using a custom genotyping array. HLA diversity (measured by heterozygosity...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Age Factors
• Share to Antibodies, Monoclonal, Humanized